Analysts Set Expectations for Indaptus Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Indaptus Therapeutics in a report issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.38) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07.

Indaptus Therapeutics Stock Performance

NASDAQ:INDP opened at $2.65 on Tuesday. Indaptus Therapeutics has a one year low of $1.56 and a one year high of $4.08. The business has a fifty day moving average price of $2.09 and a 200-day moving average price of $2.10.

Institutional Investors Weigh In On Indaptus Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Indaptus Therapeutics by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after buying an additional 5,517 shares in the last quarter. Northern Trust Corp bought a new position in shares of Indaptus Therapeutics in the 1st quarter valued at about $41,000. Citadel Advisors LLC bought a new position in shares of Indaptus Therapeutics in the 4th quarter valued at about $29,000. State Street Corp bought a new position in shares of Indaptus Therapeutics in the 1st quarter valued at about $78,000. Finally, Renaissance Technologies LLC bought a new position in shares of Indaptus Therapeutics in the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.